Medicaid Programs Should Be Able To ‘Compel’ Value-Based Contracts, State Association Official Says
Executive Summary
Existing value-based contracts, which are voluntary for manufacturers, do not lower costs for states, National Association of Medicaid Directors executive director Matt Salo suggests.
You may also be interested in...
Higher Medicaid Rebates For Expedited Approvals Offer Modest Savings But Target Growing Concern
As MACPAC moves toward formal recommendations, a CBO analysis finds that differential Medicaid rebates for drugs approved through the accelerated pathway could save the federal government up to $1bn over five years.
Tennessee Medicaid Gets US Approval For Closed Formulary As Part Of ‘Capped’ Spending Program
Demonstration, which may not survive scrutiny from the Biden Administration, includes some protections, such as prohibiting Tennessee from excluding drugs described in the Medicare Part D protected classes policy.
Louisiana Subscription Contract For Generic Epclusa About Access, Not Discounts
Innovative purchasing model is not designed to solve the problem of high drug costs, experts point out during a recent discussion at the Brookings Institution.